Infuseon Therapeutics inked a deal this week with OncoSynergy to evaluate a glioblastoma therapeutic with the Cleveland Clinic spinout’s novel delivery device.
The alliance hopes to demonstrate proof-of-concept that OncoSynergy’s candidate can be successfully delivered directly to a patient’s brain using the device in a Phase I glioblastoma trial.
Get the full story at our sister site, Drug Delivery Business News.
The post Cleveland Clinic spinout Infuseon inks deal with OncoSynergy appeared first on MassDevice.